GLP-1 Peptide Atlas, by Delfa

Active not recruitingPhase 1, PHASE2

Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults

Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults

Lead sponsor

University of Yaounde 1

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

248

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 25-34

Primary endpoints

•Effect of Dyglomera® and CQR-300® on participants GLP-1 level•BMI, change•Fasting glucose, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06827002

Org study IDJAOFCissusDyglo

Secondary IDBTC-JIRB2023-084University of Yaounde I IRB

Secondary IDJAOF122025J & A Oben Foundation

Secondary IDN°2014/08/488/CE/CNERSH/SPNational Ethics Committee of Cameroon

Timeline

Milestones

Study start2023-03-29actual

Study first posted2025-02-14actual

Primary completion2026-02-23actual

Last update posted2026-05-15actual

Study completion2026-08estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Healthy males and non-pregnant/non-lactating females

•Participants aged 18 to 65 years old

•Participants with BMI between 25 and 34 kg/m²

•Participants willing to comply with the study protocol

Exclusion criteria

•Participants younger than 18 years or older than 65 years

•Participants not available for the study period

•Morbid obesity (BMI > 34.9 kg/m²)

•Diabetes mellitus requiring daily insulin management

•Pregnancy or breastfeeding

•Active infection

•Systemic diseases, including HIV/AIDS, Active hepatitis, Clinical signs of active malignancy within the past 5 years

•Use of any medication or natural health product that might affect the parameters of interest in this study

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other (unclassified)

Glycemic / diabetes

Cardiometabolic biomarkers

Other clinical outcomes

Weight & body composition

3 endpoints

Primary/protocol endpoint

Effect of Dyglomera® and CQR-300® on participants BMI

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

BMI, change

change from baseline, improvement

Primary/protocol endpoint

Effect of Dyglomera® and CQR-300® on participants Body Fat percentage

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

change from baseline, improvement

Primary/protocol endpoint

Effect of Dyglomera® and CQR-300® on participants Body weight

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Effect of Dyglomera® and CQR-300® on participants Fasting blood glucose

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint/low confidence

Effect of Dyglomera® and CQR-300® on participants Lipid Profile

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

change from baseline, improvement

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Effect of Dyglomera® and CQR-300® on participants' energy Intake

Time frame:Week 12

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Effect of Dyglomera® and CQR-300® on participants GLP-1 level

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

concentration, descriptive

Primary/protocol endpoint/low confidence

Effect of Dyglomera® and CQR-300® on participants DPP4 activity

Time frame:Baseline (Week 0), Week 4, Week 8, and Week 12

percent change from baseline, descriptive

Publications (8)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Diabetes care2017 Feb (month)PMID27659407doi:10.2337/dc15-1707via CT.gov background
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.
Diabetology & metabolic syndrome2017 (year)PMID28450900doi:10.1186/s13098-017-0226-0via CT.gov background
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.
Diabetology & metabolic syndrome2015 (year)PMID26288659doi:10.1186/s13098-015-0059-7via CT.gov background
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
The Journal of endocrinology2014 Apr (month)PMID24323912doi:10.1530/JOE-13-0414via CT.gov background
Adverse Effects of GLP-1 Receptor Agonists.
The review of diabetic studies : RDS2014 Fall-Winter (year)PMID26177483doi:10.1900/RDS.2014.11.202via CT.gov background
The epidemiology of pancreatitis and pancreatic cancer.
Gastroenterology2013 Jun (month)PMID23622135doi:10.1053/j.gastro.2013.01.068via CT.gov background
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2004 Nov-Dec (year)PMID15655721doi:10.1055/s-2004-826178via CT.gov background
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Clinical chemistry1972 Jun (month)PMID4337382via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.